Navigation Links
Lilly and Medtronic Announce Drug-Device Collaboration for Parkinson's Disease
Date:4/26/2011

INDIANAPOLIS and MINNEAPOLIS, April 26, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Medtronic, Inc. (NYSE: MDT) today announced they have entered into a collaboration to research and develop a new approach to treating Parkinson's disease that involves delivering a potential new  medicine to the brain using an implantable drug delivery system. The goal of the collaboration is to develop a therapeutic approach for Parkinson's disease that combines the strengths of Lilly's biologic, a modified form of glial cell derived neurotrophic factor (GDNF), with Medtronic's implantable drug infusion system technology.

"We believe we have biosynthetically engineered this GDNF variant to overcome technical hurdles of previous research in this area and are hopeful that early testing of our biologic with Medtronic's device will provide the necessary data to safely advance into human studies," said Michael L. Hutton, Ph.D., chief scientific officer of the neurodegeneration team at Lilly. "By collaborating with Medtronic from the earliest phase of research, we are maximizing the potential for this therapy's efficient and effective development."

Parkinson's disease is a neurodegenerative condition caused by progressive loss of neurons in the brain that produce dopamine, a chemical messenger responsible for transmitting signals that allow for coordination of movement. As a result, patients with Parkinson's disease experience balance problems, tremors and muscular stiffness, among other symptoms which worsen over time.  It is estimated that 7 million to 10 million people worldwide are living with Parkinson's disease(i) and there is no cure. Around the world, April is Parkinson's Awareness Month.

Applying its expertise in biotechnology, Lilly has designed its GDNF variant with the intent to achieve increased distribution in targeted brain regions. Medtronic has developed a drug pump and specially designed catheter to enable precise delivery of the GDNF variant into a targeted area of the brain consistently over time. This combination of a novel GDNF variant, paired with an optimized delivery system, has the potential to impact the neurodegeneration that leads to worsening symptoms and progression of Parkinson's disease.  

"Our collaboration with Lilly is bringing together the expertise of both companies to develop a new approach to the treatment of Parkinson's disease," said Steve Oesterle, M.D., senior vice president of Medicine and Technology at Medtronic.  "One of the most significant challenges in delivering a biologic treatment for neurodegenerative diseases is crossing the blood brain barrier.  We have extensive experience in targeted drug delivery and technology that allow delivery of therapeutic agents directly to the brain."

"While a potential treatment approach resulting from this research is many years away, we are heartened by Lilly and Medtronic's commitment to develop a neurotrophic-based therapy for Parkinson's disease," said Katie Hood, CEO of The Michael J. Fox Foundation for Parkinson's Research. "Our foundation has funded separate, ongoing work in neurotrophic factors for years, and we continue to believe in their promise to lead to a critically needed disease-modifying treatment for Parkinson's."

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

About Medtronic

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health, and extending life for millions of people around the world.

P-LLY

This news release contains forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements are based upon the current beliefs and expectations of the managements of Lilly and Medtronic, and are subject to significant risks and uncertainties. Actual results may differ materially from those set forth in the forward-looking statements. The companies undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause their results to differ materially from those described in the forward-looking statements can be found in their most recent Forms 10-K and 10-Q, and each company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

(i)  The Parkinson's Disease Foundation, http://www.pdf.org/en/parkinson_statistics. Accessed 3/18/2011.

(Logo:  http://photos.prnewswire.com/prnh/20031219/LLYLOGO)

(Logo:  http://photos.prnewswire.com/prnh/20080519/DE19417LOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017  Aprima Medical ... records (EHR), practice management (PM) and revenue cycle ... the acquisition of a former reseller Healthcare Data ... of the agreement, Aprima will assume full support ... in 125 medical practices across 15 states. Financial ...
(Date:1/18/2017)... 18, 2017 The Philadelphia Pediatric Medical Device Consortium ... devices for children. The Consortium chose those companies ... of $50,000 each. The devices under development are ... a hand-operated rapid blood delivery system for emergency situations and ... ...
(Date:1/18/2017)... , Jan. 18, 2017   Regenicin, Inc. ... biotechnology company specializing in the development and commercialization of ... tissues and organs, recently reported the Company,s operating results ... 2017. As the Company described in its ... a year of substantial accomplishments. The Company,s contract laboratory ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... 19, 2017 , ... Attorney Robert “RC” Pate , founder of The ... the Triumph Over Kid Cancer foundation. Each year, 175,000 children are diagnosed with pediatric ... firsthand the effect of the critical funding gap for research into pediatric cancer research. ...
(Date:1/19/2017)... ... ... Connecticut Dermatology Group (CDG) is proud and excited to welcome back to the ... brings an extensive background in cutting-edge dermatology care and research to Connecticut’s largest ... Kim to the CDG team” said President and Managing Partner Dr. Steven A. Kolenik ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... hosts the Atlanta Breast Surgery Symposium, a conference where hundreds of surgeons from ... in breast surgery. Covering topics from cosmetic breast augmentation to breast ...
(Date:1/18/2017)... ... ... From a health perspective, 2017 will clearly be the Year of the Gut. ... health and general physical well-being. The New York Times suggested a “ Gut Makeover ... Charlottesville restaurant, good gut health is clearly on the menu. Threepenny Cafe ...
(Date:1/18/2017)... ... January 18, 2017 , ... The V Foundation for ... V, its official endurance training and fundraising team, to compete in the Boston Marathon ... those inspired to finish the world’s oldest annual marathon to join Team V and ...
Breaking Medicine News(10 mins):